Global Tuberculosis Diagnosis and Treatment Market, 2025-2035

Description

List of Tables

Global Tuberculosis Diagnosis and Treatment Market Size, Share & Trends Analysis by Diagnosis Type (Laboratory Testing, Nucleic Acid Tests, Skin Tests, Blood Tests, Imaging Tests, Sputum Tests, Smear Microscopy, Culture-Based Tests, Serological Tests, Drug Susceptibility Testing (DST), and Others), By Treatment Type (First-Line Treatment, Second-Line Treatment, and Others), By End-User (Hospitals, Diagnostic Laboratories, Research Institutes, and Others), Forecast Period (2026-2035)

Industry Overview

Tuberculosis diagnosis and treatment market was valued at $2.4 billion in 2025 and is projected to reach $4.3 billion by 2035, growing at a CAGR of 5.4% during the forecast Period (2026-2035). The market focuses on the detection, monitoring, and management of tuberculosis (TB), a persistent infectious disease affecting millions worldwide. The market encompasses diagnostic solutions, including molecular tests, nucleic acid amplification tests, and skin-based assays, alongside first-line and second-line treatment regimens. Growth is driven by high disease prevalence, the emergence of drug-resistant TB strains, technological advancements in rapid diagnostics, and government and global health initiatives supporting early detection and treatment access, particularly in high-burden regions.

Market Dynamics

Persistently High TB Disease Burden and Rising Drug-Resistant Cases

The global prevalence of tuberculosis (TB) remains high, particularly in low- and middle-income countries with significant public health challenges. Despite ongoing control efforts, millions of new TB cases are reported each year, and the disease continues to be a leading infectious cause of mortality worldwide. This persistent disease burden fuels sustained demand for both diagnostic tools and effective treatments, as healthcare systems require reliable solutions to detect and manage TB infections in diverse populations. Additionally, the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains has further intensified market growth, necessitating advanced diagnostics capable of identifying drug resistance and new therapeutic regimens tailored to resistant forms of TB, thereby driving investment and innovation across the value chain.

Technological Advancements in Diagnostics and Personalized Treatment Approaches

Rapid technological innovation in diagnostic solutions such as molecular assays, nucleic acid amplification tests (NAATs), point-of-care (POC) platforms, and AI-enabled imaging tools is a major growth driver in the market. These advanced diagnostics deliver faster, more accurate results compared to traditional methods like sputum microscopy or culture tests, enabling earlier detection of both active and latent TB infections and facilitating timely treatment decisions. Moreover, progress toward personalized medicine and tailored therapeutic strategies is gaining traction, particularly for complex cases involving drug resistance or co-infection with HIV, enabling more effective treatment outcomes with fewer side effects.

Increased Government and Global Health Funding Initiatives

Heightened governmental support and international funding programs are crucial drivers of market expansion, as they enhance access to diagnostics and treatment services, particularly in high-burden regions. Public health initiatives, such as national TB elimination programs and global strategies endorsed by the World Health Organization (WHO) and partners, channel financial resources toward the procurement of diagnostic kits, essential medicines, and the establishment of treatment infrastructure. Expanded funding also supports awareness campaigns, screening drives, and capacity building in laboratories and clinics, improving early detection rates and treatment uptake. The involvement of major global health financers, including the Global Fund and other multilateral organizations, further strengthens market sustainability by enabling large-scale TB control and management efforts globally.

Market Segmentation

Based on the diagnosis type, the market is segmented into laboratory testing, nucleic acid tests, skin tests, blood tests, imaging tests, sputum tests, smear microscopy, culture-based tests, serological tests, drug susceptibility testing (DST), and others.
Based on the treatment type, the market is segmented into first-line treatment, second-line treatment, and others.
Based on the end-user, the market is segmented into hospitals, diagnostic laboratories, research institutes, and others.

Laboratory Testing Segment to Grow at a Considerable Market Share

The laboratory testing segment is expected to lead the global tuberculosis diagnosis and treatment market due to its widespread adoption, accuracy, and critical role in early detection and management of TB. Laboratory testing encompasses a broad range of diagnostic methods, including sputum tests, smear microscopy, culture-based tests, and drug susceptibility testing (DST), which are essential for identifying both drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis. Among these, culture-based tests and DST are particularly vital for guiding treatment regimens, especially in regions with high prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB.

The dominance of this segment is driven by government initiatives and global health programs that prioritize laboratory-based TB detection as part of national TB control strategies. These programs invest heavily in laboratory infrastructure, high-quality reagents, and skilled personnel, particularly in high-burden countries such as India, China, and South Africa. Additionally, advancements in automated and high-throughput laboratory technologies have enhanced testing speed, reliability, and accessibility, enabling large-scale screening programs and early diagnosis, which is critical to reducing TB mortality. As a result, laboratory testing remains the largest and most influential segment, forming the backbone of the TB diagnostic ecosystem globally and continuing to drive the market's growth over the forecast period.

First-Line Treatment: A Key Segment in Market Growth

The first-line treatment segment is the primary driver of growth in the global tuberculosis (TB) diagnosis and treatment market. First-line treatments, which include standard anti-TB drugs such as isoniazid, rifampicin, pyrazinamide, and ethambutol, remain the cornerstone of TB management due to their proven efficacy, safety profile, and widespread availability. The high prevalence of drug-sensitive TB worldwide ensures that first-line therapies continue to dominate treatment protocols, particularly in high-burden regions across Asia and Africa.

Additionally, government healthcare programs and global health initiatives heavily focus on supplying these medications to reduce disease transmission and achieve the World Health Organization's End TB targets. The demand for first-line treatment is further reinforced by large-scale screening and early diagnosis campaigns, which increase patient enrollment in standardized treatment regimens. Hospitals and diagnostic laboratories, the primary end-users for TB care, rely extensively on first-line drugs to manage the majority of newly diagnosed cases. As awareness about TB prevention and treatment expands and healthcare infrastructure strengthens in emerging economies, the first-line treatment segment is poised to sustain its dominant market share, driving consistent revenue growth. The segment's combination of accessibility, cost-effectiveness, and critical role in national TB control programs makes it a key contributor to the overall expansion of the market.

Regional Outlook

The global tuberculosis diagnosis and treatment market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global tuberculosis diagnosis and treatment market, holding a major share due to its exceptionally high TB burden and concentrated healthcare efforts. According to the World Health Organization (WHO), India accounts for a substantial proportion of the world's tuberculosis cases, leading all other nations in the number of individuals affected by the disease. The persistent high incidence in India drives continuous demand for both advanced diagnostic solutions and effective treatment regimens, making it a central focus area for market growth and investment.

India's large population, combined with ongoing public health challenges such as tuberculosis-, HIV co-infections, and drug-resistant TB strains, reinforces the need for expanded testing, improved laboratory infrastructure, and broad access to first-line and newer therapeutic options. National programs and government strategies aimed at accelerating TB detection and treatment have stimulated procurement of molecular diagnostic platforms and consistent distribution of anti-TB drugs across public and private healthcare settings. These efforts not only address the domestic public health burden but also attract global partnerships and funding initiatives that further strengthen the diagnostic and treatment market ecosystem.

As a result, advancements in diagnostics, policy focus on elimination, and extensive treatment networks in India underpin its dominant role in shaping the global tuberculosis market landscape, influencing trends, resource allocation, and strategic planning across the healthcare sector.

Market Players Outlook

The major companies operating in the global tuberculosis diagnosis and treatment market include Becton, Dickinson and Company (BD), bioMerieux SA, Cepheid (Danaher Corporation), F. Hoffmann-La Roche Ltd., QIAGEN N.V, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

In March 2026, the World Health Organization (WHO) recently recommended new near-point-of-care diagnostic tests that can be used close to where patients seek care, are portable, operate on battery power, and deliver results in under one hour. These simpler molecular tests are significantly cheaper than many existing diagnostics and help accelerate initiation of treatment by reducing delays. They also support easier sample collection, including innovative tongue swab methods, enabling TB testing for individuals unable to produce sputum, particularly children and people with extrapulmonary TB.

The Report Covers:

Market value data analysis for 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global tuberculosis diagnosis and treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2029329

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Tuberculosis Diagnosis and Treatment Market Sales Analysis - Diagnosis Type | Treatment Type | End-User ($ Million)
Tuberculosis Diagnosis and Treatment Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Tuberculosis Diagnosis and Treatment Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Tuberculosis Diagnosis and Treatment Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Tuberculosis Diagnosis and Treatment Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Tuberculosis Diagnosis and Treatment Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Tuberculosis Diagnosis and Treatment Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Tuberculosis Diagnosis and Treatment Market Revenue and Share by Manufacturers
Tuberculosis Diagnosis and Treatment Treatment Type Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Becton, Dickinson and Company (BD)
  - 4.2.1.1. Overview
  - 4.2.1.2. Treatment Type Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. bioMerieux SA
  - 4.2.2.1. Overview
  - 4.2.2.2. Treatment Type Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Cepheid (Danaher Corporation)
  - 4.2.3.1. Overview
  - 4.2.3.2. Treatment Type Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. F. Hoffmann-La Roche Ltd.
  - 4.2.4.1. Overview
  - 4.2.4.2. Treatment Type Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. QIAGEN N.V
  - 4.2.5.1. Overview
  - 4.2.5.2. Treatment Type Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Treatment Type Launch
- 4.3.3. Partnership And Collaboration

5. Global Tuberculosis Diagnosis and Treatment Market Sales Analysis by Diagnosis Type ($ Million)

5.1. Laboratory Testing
5.2. Nucleic Acid Tests
5.3. Skin Tests
5.4. Blood Tests
5.5. Imaging Tests
5.6. Sputum Tests
5.7. Smear Microscopy
5.8. Culture-Based Tests
5.9. Serological Tests
5.10. Drug Susceptibility Testing (DST)
5.11. Others

6. Global Tuberculosis Diagnosis and Treatment Market Sales Analysis by Treatment Type ($ Million)

6.1. First-Line Treatment
6.2. Second-Line Treatment
6.3. Others

7. Global Tuberculosis Diagnosis and Treatment Market Sales Analysis by End-User ($ Million)

7.1. Hospitals
7.2. Diagnostic Laboratories
7.3. Research Institutes
7.4. Others

8. Regional Analysis

8.1. North American Tuberculosis Diagnosis and Treatment Market Sales Analysis - Diagnosis Type | Treatment Type | End-User | Country ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Tuberculosis Diagnosis and Treatment Market Sales Analysis - Diagnosis Type | Treatment Type | End-User | Country ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Tuberculosis Diagnosis and Treatment Market Sales Analysis - Diagnosis Type | Treatment Type | End-User | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Tuberculosis Diagnosis and Treatment Market Sales Analysis - Diagnosis Type | Treatment Type | End-User | Country ($ Million)
Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. Abbott Laboratories
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. Becton, Dickinson and Co. (BD)
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. Biofabri S L
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. bioMerieux SA
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Cepheid (Danaher Corporation)
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. F. Hoffmann-La Roche Ltd.
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. GlaxoSmithKline plc
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Hain Lifescience GmbH
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. Hologic, Inc.
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. Johnson & Johnson
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. Lupin Ltd.
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. Molbio Diagnostics Pvt. Ltd.
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. Novartis AG
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. Otsuka Pharmaceutical Co., Ltd.
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. Oxford Immunotec
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. Pfizer Inc.
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. Sanofi S.A.
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. Serum Institute of India Pvt. Ltd.
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. Thermo Fisher Scientific Inc.
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies